A

Adocia SA
PAR:ADOC

Watchlist Manager
Adocia SA
PAR:ADOC
Watchlist
Price: 4.96 EUR 16.43%
Market Cap: 89.7m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ADOC stock under the Base Case scenario is 4.6 EUR. Compared to the current market price of 4.96 EUR, Adocia SA is Overvalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADOC Relative Value
Base Case
4.6 EUR
Overvaluation 7%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

9.6
P/S
P/S
Price to Sales
9.6
vs History
74
vs Industry
12
Median 3Y
11.7
Median 5Y
72.2
Industry
7.6
Forward
1.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-7.7
Median 5Y
-7.8
Industry
24.2
Forward
1.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-6.9
Industry
20.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.2
Industry
22.9
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-16.7
Median 5Y
-13
Industry
2.9
More Details
9.7
EV/S
EV/S
Enterprise Value to Sales
9.7
vs History
74
vs Industry
9
Median 3Y
11.8
Median 5Y
74.2
Industry
7.9
Forward
1.4
More Details
11.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
11.1
vs History
14
vs Industry
12
Median 3Y
5.6
Median 5Y
0
Industry
10
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-10
Industry
5.1
Forward
1.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-9.3
Industry
5.1
Forward
1.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-7
Industry
5.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-6.5
Median 5Y
-6.9
Industry
4.2
More Details
5.7
EV/IC
EV/IC
Enterprise Value to IC
5.7
vs History
88
vs Industry
24
Median 3Y
9.6
Median 5Y
12.7
Industry
5.2
More Details

Multiples Across Competitors

ADOC Competitors Multiples
Adocia SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Adocia SA
PAR:ADOC
89.7m EUR 9.6 -9.6 -13.4 -12.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 698 808.5 -160 165.4 -194 491.9 -192 272.6
US
Abbvie Inc
NYSE:ABBV
337.9B USD 5.9 81.3 15.5 22.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
165.8B USD 4.9 27.9 14.9 24.5
US
Gilead Sciences Inc
NASDAQ:GILD
141.4B USD 4.9 23.7 10.3 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.6B USD 11 -123.9 26.4 27.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 090.6 -533.5 -580.9 -565.4
AU
CSL Ltd
ASX:CSL
130.4B AUD 5.7 31.3 19.1 23.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.9B USD 4.4 13.8 12.3 13.9
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
FR
A
Adocia SA
PAR:ADOC
Average P/S: 3 097 751.9
9.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 698 808.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
374 305.7
140%
2 673.6
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11
10%
1.1
US
E
Epizyme Inc
F:EPE
2 090.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
FR
A
Adocia SA
PAR:ADOC
Average P/E: 35.6
Negative Multiple: -9.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 165.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.3
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
27.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.7
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -123.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.5 N/A N/A
AU
CSL Ltd
ASX:CSL
31.3
16%
2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
A
Adocia SA
PAR:ADOC
Average EV/EBITDA: 16.4
Negative Multiple: -13.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 491.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.9
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.9 N/A N/A
AU
CSL Ltd
ASX:CSL
19.1
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
A
Adocia SA
PAR:ADOC
Average EV/EBIT: 21.2
Negative Multiple: -12.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 272.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.5
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.4 N/A N/A
AU
CSL Ltd
ASX:CSL
23.9
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A

See Also

Summary
ADOC intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADOC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADOC stock valuation using valuation multiples.
Wall Street Estimates
ADOC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADOC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.